METAVIA INC. Fair Value, Liability, Recurring Basis, Still Held, Unrealized Gain (Loss)
METAVIA INC. (MTVA) reported Fair Value, Liability, Recurring Basis, Still Held, Unrealized Gain (Loss) of $850.00 thousand for the 12-month period ending 2016-12-31, per its 10-K filed 2019-03-18.
Discontinued › Income Statement › Other Income
us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss · last filed 2019-03-18
- METAVIA INC. fair value, liability, recurring basis, still held, unrealized gain (loss) for the quarter ending 2016-12-31 was $0.00.
- METAVIA INC. fair value, liability, recurring basis, still held, unrealized gain (loss) for the quarter ending 2016-09-30 was $243.00K.
- METAVIA INC. fair value, liability, recurring basis, still held, unrealized gain (loss) for the quarter ending 2016-06-30 was $629.00K.
- METAVIA INC. fair value, liability, recurring basis, still held, unrealized gain (loss) for the quarter ending 2016-03-31 was -$22.00K.
- METAVIA INC. fair value, liability, recurring basis, still held, unrealized gain (loss) for fiscal 2016 was $850.00K.
- METAVIA INC. fair value, liability, recurring basis, still held, unrealized gain (loss) for fiscal 2015 was -$297.00K, a 1750.00% decline from fiscal 2014.
- METAVIA INC. fair value, liability, recurring basis, still held, unrealized gain (loss) for fiscal 2014 was $18.00K.
| Period end | Fair Value, Liability, Recurring Basis, Still Held, Unrealized Gain (Loss) 3 month | Fair Value, Liability, Recurring Basis, Still Held, Unrealized Gain (Loss) 6 month | Fair Value, Liability, Recurring Basis, Still Held, Unrealized Gain (Loss) 9 month | Fair Value, Liability, Recurring Basis, Still Held, Unrealized Gain (Loss) 12 month | Fair Value, Liability, Recurring Basis, Still Held, Unrealized Gain (Loss) 12 month as first filed |
|---|---|---|---|---|---|
| 2016-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-18 | $243.00K derived: sum of 2 quarters · filed 2019-03-18 | $872.00K derived: sum of 3 quarters · filed 2019-03-18 | $850.00K 10-K · filed 2019-03-18 | -$850.00K 10-K · filed 2017-03-21 |
| 2016-09-30 | $243.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-13 | $872.00K derived: sum of 2 quarters · filed 2017-11-13 | $850.00K 10-Q · filed 2017-11-13 | ||
| 2016-06-30 | $629.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-14 | $607.00K 10-Q · filed 2017-08-14 | |||
| 2016-03-31 | -$22.00K 10-Q · filed 2017-05-10 | ||||
| 2015-12-31 | -$297.00K 10-K · filed 2018-03-20 | $297.00K 10-K · filed 2017-03-21 | |||
| 2014-12-31 | $18.00K 10-K · filed 2017-03-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| Theriva Biologics, Inc. (TOVX) | United States | $0.011B | |
| Azitra, Inc. (AZTR) | United States | $0.010B | -0.81 |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Medicus Pharma Ltd. (MDCX) | $0.010B | ||
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |